Mice NNP I-NP I-KP 0,4
bearing VBG I-NP I-KP 5,12
the DT B-NP I-KP 13,16
orthotopic NN I-NP I-KP 17,27
model NN I-NP I-KP 28,33
were VBD I-VP O 34,38
treated VBN I-VP O 39,46
starting VBG I-VP O 47,55
from IN I-PP O 56,60
day NN I-NP O 61,64
21 CD I-NP O 65,67
after IN I-PP O 68,73
NB NNP I-NP O 74,76
cell NN I-NP O 77,81
implant; NN I-NP O 82,89
mice NN I-NP I-KP 91,95
with IN I-PP I-KP 96,100
the DT I-NP I-KP 101,104
pseudo-metastatic JJ I-NP I-KP 105,122
model NN I-NP I-KP 123,128
received VBD I-VP O 129,137
the DT I-NP O 138,141
first JJ I-NP O 142,147
treatment NN I-NP O 148,157
4h CD I-NP O 158,160
after IN I-PP O 161,166
NB NNP I-NP O 167,169
cell NN I-NP O 170,174
injection. NN I-NP O 175,184

These DT I-NP I-KP 186,191
therapeutic JJ I-NP I-KP 192,203
schedules NNS I-NP I-KP 204,213
were VBD I-VP O 214,218
designed VBN I-VP O 219,227
to TO I-VP O 228,230
test VB I-VP I-KP 231,235
the DT I-NP I-KP 236,239
effects NNS I-NP I-KP 240,247
of IN I-PP O 248,250
our PRP$ I-NP I-KP 251,254
targeted JJ I-NP I-KP 255,263
formulations NNS I-NP I-KP 264,276
against IN I-PP O 277,284
both DT I-NP O 285,289
established VBN I-NP O 290,301
and CC O O 302,305
pseudo-metastatic JJ I-NP O 306,323
preclinical JJ I-NP I-KP 324,335
models NNS I-NP I-KP 336,342
of IN I-PP O 343,345
human JJ I-NP O 346,351
NB, NNP I-NP O 352,354
as IN I-PP O 356,358
described VBN I-NP O 359,368
[16,19]. NN I-NP O 369,376

Animals NNS I-NP I-KP 378,385
were VBD I-VP O 386,390
treated VBN I-VP O 391,398
i.v. NN I-NP O 399,402

once RB O O 404,408
a DT I-NP O 409,410
week NN I-NP O 411,415
for IN I-PP O 416,419
3 CD I-NP O 420,421
weeks NNS I-NP O 422,427
with IN I-PP O 428,432
untargeted JJ I-NP I-KP 433,443
(SL[DXR]) NN I-NP O 444,453
or CC O O 454,456
peptide-targeted JJ I-NP I-KP 457,473
SL[DXR] NNP I-NP I-KP 474,481
(5mg/kg). NN I-NP O 482,490

Scrambled VBN I-VP I-KP 492,501
peptide-functionalized JJ I-NP I-KP 502,524
liposomes NNS I-NP I-KP 525,534
were VBD I-VP O 535,539
used VBN I-VP O 540,544
as IN I-PP O 545,547
a DT I-NP O 548,549
control, NN I-NP O 550,557
and CC O O 559,562
in IN I-PP O 563,565
every DT I-NP O 566,571
experiment NN I-NP O 572,582
a DT B-NP O 583,584
group NN I-NP O 585,590
of IN I-PP O 591,593
control NN I-NP O 594,601
mice NN I-NP O 602,606
received VBD I-VP O 607,615
HEPES-buffered NNP I-NP I-KP 616,630
saline. NN I-NP I-KP 631,637

Survival JJ I-NP I-KP 639,647
times NNS I-NP I-KP 648,653
were VBD I-VP O 654,658
used VBN I-VP O 659,663
as IN I-PP O 664,666
the DT I-NP O 667,670
main JJ I-NP O 671,675
criterion NN I-NP O 676,685
for IN I-PP O 686,689
determining VBG I-VP I-KP 690,701
treatment NN I-NP I-KP 702,711
efficacy. NN I-NP I-KP 712,720

In IN I-PP O 722,724
the DT I-NP O 725,728
orthotopic NN I-NP I-KP 729,739
model, VBD I-VP I-KP 740,745
time-dependent JJ I-NP I-KP 747,761
anti-tumor JJ I-NP I-KP 762,772
activity NN I-NP I-KP 773,781
was VBD I-VP O 782,785
also RB I-VP O 786,790
evaluated VBN I-VP O 791,800
by IN I-PP O 801,803
bioluminescence NN I-NP O 804,819
imaging VBG I-NP O 820,827
(BLI) JJ I-NP O 828,833
and CC O O 834,837
X-ray JJ I-NP O 838,843
analyses. NN I-NP O 844,852

For IN I-PP O 854,857
this DT I-NP O 858,862
purpose, VBZ I-VP O 863,870
the DT I-NP I-KP 872,875
GI-LI-N NNP I-NP I-KP 876,883
cell NN I-NP I-KP 884,888
line NN I-NP I-KP 889,893
was VBD I-VP O 894,897
infected VBN I-VP I-KP 898,906
with IN I-PP O 907,911
a DT I-NP O 912,913
retrovirus NN I-NP O 914,924
expressing VBG I-VP O 925,935
the DT I-NP O 936,939
firefly NN I-NP O 940,947
luciferase NN I-NP O 948,958
gene, NN I-NP O 959,963
as IN I-PP O 965,967
previously RB I-NP O 968,978
reported VBN I-NP O 979,987
[17]; JJ I-NP O 988,992
luciferase NN I-NP I-KP 994,1004
activity NN I-NP I-KP 1005,1013
of IN I-PP O 1014,1016
retrovirally-transduced JJ I-NP I-KP 1017,1040
cells NNS I-NP I-KP 1041,1046
was VBD I-VP O 1047,1050
visualized VBN I-VP I-KP 1051,1061
in IN I-PP O 1062,1064
vivo NN I-NP O 1065,1069
by IN I-PP O 1070,1072
BLI NNP I-NP O 1073,1076
(IVIS NNP I-NP O 1077,1082
Caliper NNP I-NP O 1083,1090
Life NNP I-NP O 1091,1095
Sciences, NNP I-NP O 1096,1104
Hopkinton, NNP I-NP O 1106,1115
MA) NNP I-NP O 1117,1120
after IN I-PP O 1121,1126
a DT I-NP O 1127,1128
10min CD I-NP O 1129,1134
incubation NN I-NP O 1135,1145
with IN I-PP O 1146,1150
150Î¼g/mL CD I-NP O 1151,1159
of IN I-PP O 1160,1162
d-luciferin JJ I-NP I-KP 1163,1174
(Caliper NNP I-NP O 1175,1183
Life NNP I-NP O 1184,1188
Sciences), NNP I-NP O 1189,1198
as IN I-PP O 1200,1202
described VBN I-NP O 1203,1212
[17]. NN I-NP O 1213,1217

X-ray JJ I-NP O 1219,1224
analysis NN I-NP O 1225,1233
was VBD I-VP O 1234,1237
superimposed VBN I-VP O 1238,1250
to TO I-VP O 1251,1253
the DT I-NP O 1254,1257
luminescence NN I-NP O 1258,1270
for IN I-PP O 1271,1274
a DT I-NP O 1275,1276
better JJR I-NP O 1277,1283
visualization NN I-NP O 1284,1297
of IN I-PP O 1298,1300
the DT I-NP O 1301,1304
tumors. NN I-NP O 1305,1311

